Success for OPT 302 in the phase 3 trial would stand a better...

Success for OPT 302 in the phase 3 trial would stand a better chance of " New Drug Application" when combined with a VEG A inhibitor in a single dose/injection and would be a true Blockbuster rendering all drugs that only target VEGF A obsolete. Then whole wet AMD market could be captive to a drug that combines the benefits of VEGF A,C and D inhibition in one dose. If combined wet AMD market for VEGF A inhibitors is $16BUS annual sales then a combination drug would be worth well north of $20BUS (this is speculation)but you get my drift!!
I note the volume traded in OPT today very low and finished wide. Still some cheap stock available in the low sixties!!